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Background
Chromosomal segregation in eukaryotic cells is controlled
by a group of proteins that constitute the mitotic spindle
checkpoint (MSC). Any alteration in this checkpoint
causes chromosomal instability, mainly aneuploidy.
MAD1 is one of the MSC proteins, which has structural
and regulatory functions that influence the cell cycle
progress. MAD1 regulates positively MAD2, attracting it to
the active kinetochore, and promoting its interaction with
CDC20. This complex inhibits progression of the cell
cycle towards anaphase until all chromosomes have the
adequate alignment. Recently, it was reported a polymor-
phism at codon 558 of Mad1 gene that replaces a G for an
A, promoting the change from arginine to histidine (H).
The allelic frequencies in cancer cell lines were 67% for
A558 and 33% for G558. Data demonstrated that the H/
H phenotype affects binding between MAD1 and MAD2,
disturbing the activation of the MSC. This polymorphism
was only observed in cancer cells, but not in cells from
healthy donors. Even though, preliminary studies in our
laboratory have detected the homozygous polymorphic
variant in healthy donors. The aim of the present work
was to determine the frequency of the G558A polymor-
phism in Mad1 gene of a Mexican population, as well as
its influence on the MSC activation.
Materials and methods
Whole blood samples were obtained from 140 Mexican
healthy donors. DNA isolation was performed by the
standard protocols (phenol-chloroform-isoamilic alco-
hol) and precipitated with ice-cold ethanol. Genotyping
of Mad1 polymorphism (G558A) was performed by PCR
and restriction-enzyme digestion. After digestion, wild
type genotype generates five fragments (12, 42, 43, 50 and
94 bp), while the polymorphic variant leads the amplifi-
cation of four fragments (12, 43, 50 and 136 bp). In order
to investigate activation of the MSC in the polymorphic
individuals, cells from 27 donors were cultured and
exposed to nocodazole (0.2 μg/ml) for 2 and 6 h. Cells
were fixed and stained to analyze the mitotic index.
Results
Of the 140 studied donors, 34 had GG genotype, 74 GA
and 34 AA, with a genotypic frequency of 24.3, 51.4 and
24.3 respectively, and a frequency of 50% for both alleles.
Treatment with nocodazole induced a higher mitotic
index in lymphocytes with GG genotype, followed by the
heterozygous (GA) and finally by the homozygous AA.
Conclusion
This study demonstrates that the polymorphic variant
A558 of Mad1 gene is very frequent in healthy Mexican
individuals, and therefore is not a result of the malignant
transformation process as had been proposed. The Mad1
polymorphic variant has an influence in the cellular
response to the treatment with agents that alter the chro-
mosomal segregation. The fact that cells of the individuals
of the AA variant do not stop in metaphase after treatment
with nocodazole makes cells more sensitive to present
errors in the chromosomal segregation, which may even-
tually result in the generation of aneuploid cells.
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